Wat betsjut "Dúdlik"?
It bist draacht de mutaasje net. It sil de sykte net ûntwikkelje en sil it net trochjaan.
Hûn Canine Multiple System Degeneration In Kerry Blue Terrier (CMSD-KBT)
The Canine Multiple System Degeneration (CMSD) DNA test is essential for Kerry Blue Terrier owners to ensure their dogs' health. CMSD is a hereditary neurological disorder affecting coordination and movement in Kerry Blue Terriers. Early genetic testing helps identify carriers and affected dogs, enabling responsible breeding decisions. By using the CMSD DNA test, breeders can reduce the risk of passing this debilitating condition to future generations. This test provides accurate, reliable results, promoting the well-being of your Kerry Blue Terrier. Protect your dog’s health with the CMSD DNA test today. Regular screening supports a healthier, happier canine companion.
Ofkoarting: CMSD-KBT
Analysearre mutaasje: SERAC1 c.1536G>A
Erfskip: Autosomaal recessyf
Acronym
CMSD-KBT
Observearre frekwinsje
Klinyske earnst
Clinical klassifikaasje
Neurologyske sykten
Analysearre mutaasje
SERAC1 c.1536G>A
p.(Trp512*)
p.(Trp512*)
Mode fan erfskip
Autosomaal recessyf
Test gearfetting:
Canine Multiple System Degeneration (CMSD) is a genetic disorder affecting Kerry Blue Terriers, causing progressive neurological decline. A DNA test is available to identify carriers and affected dogs, helping breeders make informed decisions. Early detection through testing can prevent the spread of this debilitating condition within the breed. Responsible breeding practices rely on these genetic insights to maintain healthy Kerry Blue Terrier populations. Overall, the CMSD DNA test is a valuable tool for canine health management.
Beskikber út it pakket: Basic
Dizze DNA-test is opnommen fanôf ús pakket Basic - en is ek diel fan 'e pakketten Basic, Standard, Advanced, Complete.
Besjoch DNA-testpakketten →Kies it pakket dat it bêste past by jo fokken of sûnensstrategy fan jo bisten.
Understanding Canine Multiple System Degeneration in Kerry Blue Terriers (CMSD-KBT)
Canine Multiple System Degeneration (CMSD) is a progressive neurological disorder that primarily affects Kerry Blue Terriers. This condition is characterized by the degeneration of multiple systems within the nervous system, leading to a range of debilitating symptoms that can significantly impact the quality of life of affected dogs.
Symptoms of CMSD-KBT
The symptoms of CMSD-KBT typically manifest in early to mid-adulthood, although the age of onset can vary. Common signs include balance problems, difficulty walking, and a general lack of coordination. As the disease progresses, affected dogs may exhibit muscle weakness, tremors, and a decline in overall mobility. In some cases, dogs may also experience changes in behavior, such as increased anxiety or a reluctance to engage in normal activities.
Pathophysiology of CMSD-KBT
The underlying cause of CMSD-KBT lies in genetic mutations that affect the nervous system's ability to function properly. These mutations lead to the degeneration of nerve cells, which in turn causes a breakdown of communication between the brain and the body. This disruption results in the clinical symptoms observed in affected dogs. Understanding the genetic basis of CMSD-KBT is crucial for breeders and owners, as it allows for informed decisions regarding breeding practices and the management of affected animals.
Management and Care for Affected Dogs
While there is currently no cure for CMSD-KBT, management strategies can help improve the quality of life for affected dogs. Regular veterinary check-ups are essential for monitoring the progression of the disease and addressing any health concerns that arise. Physical therapy and rehabilitation exercises can assist in maintaining mobility and strength. Additionally, providing a safe and supportive environment can help dogs cope with their symptoms and enhance their overall well-being.
Konklúzje
Canine Multiple System Degeneration in Kerry Blue Terriers is a serious condition that requires attention from dog owners and breeders. By understanding the symptoms, underlying causes, and management strategies associated with CMSD-KBT, stakeholders can work towards improving the lives of affected dogs while making informed breeding decisions to reduce the prevalence of this condition in the breed.
Ras erkend foar de test: Canine Multiple System Degeneration In Kerry Blue Terrier (CMSD-KBT)
- Kerry Blue Terrier
🧬 Interpretation of genotypes CMSD-KBT
Genotype
Status
🟡 N/N
Non-carrier - Gjin risiko
🟡 N/CMSD-KBT
Carrier - Gjin risiko
❌ CMSD-KBT/CMSD-KBT
Beynfloede - At Risk
FAQ: begripe de ynterpretaasje
Is in "Carrier" serieus?
Nee, it bist is oer it algemien sûn, mar kin de mutaasje oerjaan oan har neiteam.
Wat as in bist "oandwaande" is?
It draacht twa mutearre eksimplaren. Klinyske tekens wurde ferwachte ôfhinklik fan de sykte. It moat net fokt wurde.
Wêrom binne d'r ferskillen tusken manlik / froulik?
Guon sykten binne seks-keppele, sadat harren útdrukking fariearret ôfhinklik fan de bist syn seks.
Foarsizze Offspring
N/N (non-drager)
N/CMSD-KBT (Carrier)
CMSD-KBT/CMSD-KBT (Beynfloede)
DNA Test FAQ
Wat detektearret dizze DNA-test?
This DNA test detects the mutation associated with Canine Multiple System Degeneration In Kerry Blue Terrier (CMSD-KBT) in order to identify clear, carrier, or at-risk animals.
Wêrom testje in fokdier?
DNA-testen helpt fokkers om feiliger parings te plannen en it risiko te ferminderjen fan it oerdragen fan de mutaasje nei neiteam.
Wat is de erflike modus fan dizze test?
De erflike modus rapportearre foar dizze test is Autosomal Recessive.
Hokker mutaasje wurdt analysearre yn dizze test?
This test analyses the mutation SERAC1 c.1536G>A.
Is in dragerdier needsaaklik beynfloede?
Net needsaaklik. Ynterpretaasje hinget ôf fan it erflik patroan en de resultearjende genotyp.
References
Johnson GS, Mhlanga-Mutangadura T, Morava E, Kozicz T, Taylor JF, O’Brien DP, Schnabel RD. Canine Multiple System Degeneration is Associated with Distinct SERAC1 Mutations in Two Different Dog Breeds [abstract]. Presented at the 63rd Annual Meeting of the American Society of Human Genetics in Boston, Massachusetts; 2013 Oct 22-26.